Recently, cardiovascular outcome study of GLP-1 receptor (GLP-1R) agonists showed reduction of cardiovascular events and prevention of chronic kidney disease progression in type-2 diabetic patients1–3. This evidence concerns the gene GLP1R and chronic kidney disease.